YAP1 and head and neck squamous cell carcinoma: The molecular program orchestrated by YAP is associated with poor prognosis and tumor progression in HNSCC providing a rationale for developing new therapies targeting the Hippo pathway effector comprising compounds that are already approved for other indications and are currently under preclinical evaluation (Taccioli et al., 2015; Segrelles et al., 2018).